Author:
Sapkale P. V,Jadhav S. B,Sable P. N.,
Abstract
HIV protease inhibitors were first invented between 1989 and 1994 by researchers working for the pharmaceutical companies of Hoffmann- La Roche Inc. (in Nutley, New Jersey), Abbott Laboratories and Merck & Co., Inc. HIV protease inhibitors are used in the treatment of patients with AIDS and were considered the first breakthrough in over a decade of AIDS research. Currently, there are five HIV protease inhibitors approved by FDA for the treatment of HIV infection. These drugs work at the final stage of viral replication and attempt to prevent HIV from making new copies of itself by interfering with the HIV protease enzyme. As a result, the new copies of HIV are not able to infect new cells. Occurrence of protease along with structural properties, classification of inhibitors like Saquinavir, Ritonavir, Indinavir, Nelfinavir etc and life cycle of virus confirm the role of protease inhibitor. Other parameters like adverse effect, application, structure activity relationship and dose regime shows need of medication for person suffering from HIV virus.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Subject
Drug Discovery,Pharmaceutical Science,Pharmacology
Reference82 articles.
1. 1. Barrett A. J., Rawlings N.D., Woessner J.F.: The Handbook of Proteolytic Enzymes, Academic Press, 2003, 2nd edition.
2. 2. Chem Rev. 2002, 102: 4501-4523.
3. 3. Hooper N.M.: Proteases in Biology and Medicine. London Portland Press, 2002, 90.
4. 4. Puente X.S., Sanchez L.M., Overall C.M., Lopez-Otin C.: Human and Mouse Proteases: a Comparative Genomic Approach, Nat Rev Genet.
5. 5. Rang H.P., Dale M.M., Ritter J.M., Flower, R.J.: Rang and Dale’s Pharmacology Philadelphia Churchill Livingstone Elsevier, 2007, 6th edition, 234-236.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献